# SUPPLEMENTAL MATERIAL

**Table S1. Baseline characteristics according to CKD stages.**

| | Total (n=1741) | Stage 1 (n=579) | Stage 2 (n=627) | Stage 3 (n=323) | Stage 4 (n=141) | Stage 5 (n=71) | P for trend[‡‡] |
|---|---|---|---|---|---|---|---|
| **Age (years)** | 60.8 ± 11.4 | 55.9 ± 10.7 | 63.6 ± 0.4 | 62.3 ± 11.4 | 59.3 ± 12.7 | 57.9 ± 11.7 | <0.001 |
| **Men (%)** | 953 (54.7) | 300 (51.8) | 359 (57.3) | 192 (59.4) | 71 (50.4) | 31 (43.7) | 0.866 |
| **Body mass index (kg/m²)** | 25.3 ± 3.8 | 25.4 ± 4.2 | 25.5 ± 3.4 | 25.3 ± 3.8 | 24.8 ± 4.1 | 23.6 ± 3.4 | 0.017 |
| **Waist to hip ratio** | 0.93 ± 0.07 | 0.92 ± 0.06 | 0.93 ± 0.07 | 0.94 ± 0.07 | 0.93 ± 0.08 | 0.92 ± 0.08 | <0.001 |
| **ECW/TBW** | 0.386 ± 0.016 | 0.384 ± 0.020 | 0.385 ± 0.014 | 0.388 ± 0.013 | 0.391 ± 0.018 | 0.392 ± 0.018 | <0.001 |
| **ECW/TBW ≥0.390** | 518 (29.8) | 107 (27.1) | 170 (27.1) | 124 (38.4) | 77 (54.6) | 40 (56.3) | <0.001 |
| **ECW/TBW ≥0.400** | 110 (6.3) | 16 (2.8) | 26 (4.1) | 25 (7.7) | 27 (19.1) | 16 (22.5) | <0.001 |
| **Pulse pressure (mmHg)** [*] | 48.7 ± 22.9 | 38.6 ± 21.3 | 42.0 ± 22.8 | 44.4 ± 21.8 | 49.7 ± 21.6 | 53.7 ± 18.8 | <0.001 |
| **Diabetes (%)** | 730 (42.1) | 214 (37.1) | 266 (42.8) | 160 (49.5) | 63 (44.7) | 27 (28.6) | 0.019 |
| **Hypertension (%)** | 1474 (85.0) | 460 (79.7) | 541 (87.0) | 288 (89.2) | 124 (87.9) | 61 (85.9) | 0.001 |
| **Cardiovascular disease (%)**[‡] | 750 (43.3) | 281 (48.7) | 341 (54.8) | 95 (29.4) | 22 (15.7) | 11 (15.9) | <0.001 |
| **Smoking (%)** | 781 (45.0) | 249 (43.2) | 287 (45.8) | 163 (50.8) | 57 (40.7) | 25 (35.2) | 0.871 |
| **CACS** [†] | 22.0 (0.0 – 189.3) | 0.0 (0.0 – 80.5) | 43.7 (0.0 – 256.5) | 45.2 (0.0 – 267.0) | 42.1 (0.0 – 255.7) | 20.1 (0.0 – 132.0) | <0.001 |
| **CAC (%)**[§] | 251 (14.4) | 41 (7.1) | 104 (16.6) | 68 (21.1) | 24 (17.0) | 14 (19.7) | <0.001 |
| **Laboratory findings** | | | | | | | |
| eGFR (mL•min-1•1.73 m⁻²) | 72.2 ± 28.6 | 100.6 ± 7.9 | 77.4 ± 8.7 | 46.5 ± 8.8 | 22.7 ± 4.3 | 10.8 ± 2.7 | <0.001 |
| Hemoglobin (g/dL) | 13.5 ± 2.0 | 14.3 ± 1.5 | 14.0 ± 1.7 | 13.2 ± 2.0 | 11.3 ± 1.3 | 10.4 ± 1.4 | <0.001 |
| Total cholesterol (mg/dL) | 174.1 ± 38.2 | 176.5 ± 38.8 | 172.3 ± 34.0 | 173.7 ± 41.7 | 177.8 ± 43.6 | 166.5 ± 38.8 | 0.070 |
| LDL (mg/dL) | 96.2 ± 30.9 | 98.2 ± 32.2 | 94.8 ± 29.3 | 94.3 ± 29.8 | 100.5 ± 34.8 | 90.4 ± 19.2 | 0.165 |
| HDL (mg/dL) | 49.5 ± 13.5 | 51.5 ± 13.5 | 50.8 ± 12.6 | 48.1 ± 14.5 | 45.5 ± 12.7 | 41.5 ± 12.7 | <0.001 |
| Triglyceride (mg/dL) | 139.2 ± 79.9 | 134.7 ± 79.4 | 136.9 ± 76.7 | 148.5 ± 92.0 | 144.7 ± 63.3 | 146.2 ± 80.5 | <0.001 |
| Albumin (g/dL) | 4.2 ± 0.3 | 4.3 ± 0.3 | 4.3 ± 0.3 | 4.2 ± 0.4 | 4.0 ± 0.4 | 3.9 ± 0.4 | <0.001 |
| Calcium (mg/dL) | 9.15 ± 0.46 | 9.17 ± 0.38 | 9.22 ± 0.42 | 9.16 ± 0.46 | 8.95 ± 0.54 | 8.65 ± 0.68 | <0.001 |
| Phosphate (mg/dL) | 3.63 ± 0.55 | 3.61 ± 0.48 | 3.52 ± 0.50 | 3.60 ± 0.52 | 3.86 ± 0.51 | 4.38 ± 0.93 | <0.001 |
| Sodium (mmol/L) | 141.4 ± 2.2 | 141.2 ± 2.2 | 141.5 ± 2.2 | 141.6 ± 2.4 | 141.5 ± 2.4 | 140.9 ± 3.1 | 0.028 |
| Potassium (mmol/L) | 4.6 ± 0.5 | 4.4 ± 0.4 | 4.5 ± 0.4 | 4.7 ± 0.5 | 5.0 ± 0.5 | 4.9 ± 0.5 | <0.001 |
| Chloride (mmol/L) | 105.3 ± 4.8 | 102.7 ± 2.7 | 103.1 ± 2.5 | 104.3 ± 3.4 | 106.5 ± 3.3 | 105.3 ± 4.8 | <0.001 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| hs-CRP (mg/L)[†] | 0.8 (0.5 – 1.5) | 0.8 (0.5 – 1.5) | 0.8 (0.5 – 1.4) | 0.9 (0.6 – 1.7) | 0.8 (0.5 – 2.3) | 0.8 (0.5 – 1.8) | 0.016 |
| uACR (mg/gCr)[†] | 4.8 (1.1 – 37.9) | 1.5 (0.7 – 7.2) | 2.6 (0.9 – 9.5) | 14.2 (3.1 – 57.8) | 64.8 (26.5 – 154.0) | 82.2 (36.8 – 186.2) | <0.001 |
| **Medications** | | | | | | | |
| Antihypertensive drugs[∥] | 1335 (76.7) | 407 (70.3) | 483 (77.0) | 261 (80.8) | 122 (86.5) | 62 (87.3) | <0.001 |
| Lipid lowering agents[#] | 955 (54.9) | 319 (55.1) | 384 (61.2) | 156 (48.3) | 65 (46.1) | 31 (43.7) | 0.002 |
| Diuretics | 429 (24.6) | 109 (18.8) | 173 (27.6) | 80 (24.8) | 42 (29.8) | 25 (35.2) | <0.001 |
| Antithrombotic agents[**] | 667 (38.3) | 199 (34.4) | 284 (45.3) | 114 (35.3) | 47 (33.3) | 23 (32.4) | 0.540 |
| Oral calcium | 22 (1.3) | 0 (0.0) | 5 (0.8) | 6 (1.9) | 3 (2.1) | 8 (11.3) | <0.001 |
| Calcium-based phosphate binder | 6 (0.3) | 0 (0.0) | 0 (0.0) | 1 (0.3) | 2 (1.4) | 3 (4.2) | <0.001 |
| Non-Ca-based phosphate binder | 1 (0.1) | 0 (0.0) | 0 (0.0) | 1 (0.3) | 0 (0.0) | 0 (0.0) | 0.429 |
| Phosphate binders[∫] | 7 (0.4) | 0 (0.0) | 0 (0.0) | 2 (0.6) | 2 (1.4) | 3 (4.2) | <0.001 |

*Mean value of pulse pressure measured by 24-hour ambulatory blood pressure monitoring, [†]Kruskal-Wallis test, [‡]Cardiovascular diseases included coronary occlusive disease, ischemic heart disease, congestive heart failure, arrhythmia, atherosclerosis, and cerebrovascular disease., [§]A total CACS ≥ 400 was defined as CAC., [∥] Antihypertensive drugs included angiotensin receptor blockers, angiotensin-converting enzyme inhibitors, calcium channel blocker, β-blocker, and α-blocker., [#] Lipid lowering agents included statin, fibrate, and nicotinic acid., [**]Antithrombotic agents included aspirin, other anti-platelets and anti-coagulants., [∫] Phosphate binders included both calcium-based and non-calcium-based phosphate binders, and [‡‡]P values by the Mantel–Haenszel's linear by linear association method or Jonckheere-Terpstra test

ECF/TBW, extracellular water to total body water ratio; CKD, chronic kidney disease; CACS, coronary artery calcium score; CAC, coronary artery calcification; eGFR, estimated glomerular filtration rate; LDL, low density lipoprotein cholesterol; HDL, high density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; uACR, urine albumin to creatinine ratio

**Table S2. Univariate linear regression analysis of variables associated with extracellular fluid status.**

| | β | 95% CI | *P* |
|---|---|---|---|
| **Age (per 1 year)** | 0.029 | 0.023 – 0.036 | <0.001 |
| **Men (vs. Women)** | -0.509 | -0.660 – -0.359 | <0.001 |
| **Body mass index (per 1 kg/m²)** | -0.043 | -0.063 – -0.023 | <0.001 |
| **Waist to hip ratio (per 0.01)** | 0.012 | 0.001 – 0.023 | 0.037 |
| **Pulse pressure (per 1 mmHg)†** | 0.005 | 0.002 – 0.008 | 0.004 |
| **Hypertension** | -0.026 | -0.238 – 0.189 | 0.815 |
| **Diabetes** | 0.431 | 0.277 – 0.583 | <0.001 |
| **Cardiovascular diseases ‡** | -0.046 | -0.197 – 0.108 | 0.556 |
| **Smoking history** | -0.484 | -0.635 – -0.332 | <0.001 |
| **CACS (per 1 log) \*** | 0.352 | 0.250 – 0.453 | <0.001 |
| **Laboratory findings** | | | |
| eGFR (per 1 mL•min-1•1.73 m⁻²) | -0.009 | -0.012 – -0.006 | <0.001 |
| Hemoglobin (per 1 g/dL) | -0.254 | -0.293 – -0.215 | <0.001 |
| Total cholesterol (per 1 mg/dL) | -0.002 | -0.004 – 0.000 | 0.024 |
| LDL (per 1 mg/dL) | -0.002 | -0.004 – 0.001 | 0.157 |
| HDL (per 1 mg/dL) | 0.003 | -0.003 – 0.009 | 0.355 |
| Triglyceride (per 1 mg/dL) | -0.002 | -0.003 – -0.001 | <0.001 |
| Albumin (per 1 g/dL) | -1.073 | -1.292 – -0.853 | <0.001 |
| Calcium (per 1 mg/dL) | -0.475 | -0.641 – -0.309 | <0.001 |
| Phosphate (per 1 mg/dL) | 0.238 | 0.102 – 0.379 | 0.001 |
| Sodium | 0.032 | -0.005 – 0.069 | 0.091 |
| Potassium | 0.177 | -0.002 – 0.358 | 0.054 |
| Chloride | 0.064 | 0.037 – 0.091 | <0.001 |
| hs-CRP (per 1 log) \* | 0.224 | -0.493 – 0.960 | 0.544 |
| uACR (per 1og) \* | 0.232 | 0.021 – 0.441 | 0.031 |
| **Medications** | | | |
| Antihypertensive drugs § | -0.132 | -0.311 – 0.049 | 0.150 |
| Lipid lowering agents ‖ | -0.016 | -0.168 – 0.138 | 0.834 |
| Diuretics | -0.161 | -0.016 – 0.336 | 0.073 |
| Antithrombotic agents # | 0.028 | -0.126 – 0.186 | 0.723 |
| Oral calcium | 0.280 | -0.401 – 0.960 | 0.420 |
| Phosphate binders \*\* | 0.656 | -0.545 – 1.857 | 0.284 |

\* Log transformed, † Mean value of pulse pressure measured by 24-hour ambulatory blood pressure monitoring, ‡ Cardiovascular diseases included coronary occlusive disease, ischemic heart disease, congestive heart failure, arrhythmia, atherosclerosis, and cerebrovascular disease., § Antihypertensive drugs included angiotensin receptor blockers, angiotensin-converting enzyme inhibitors, calcium channel blocker, β-blocker, and α-blocker., ‖ Lipid lowering agents included statin, fibrate, and nicotinic acid., # Antithrombotic agents included aspirin, other anti-platelets and anti-coagulants., \*\* Phosphate binders included both calcium-based and non-calcium-based phosphate binders.

CI, confidence interval; CACS, coronary artery calcium score; eGFR, estimated glomerular filtration rate; LDL, low density lipoprotein cholesterol; HDL, high density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; uACR, urine albumin to creatinine ratio

**Table S3**. **Univariable logistic regression analyses for presence of coronary artery calcification[*].**

| | Univariable | | |
|---|---|---|---|
| | **OR** | **95% CI** | **P** |
| **Age (per 1 year)** | 1.055 | 1.040 – 1.070 | <0.001 |
| **Men (vs. Women)** | 1.944 | 1.463 – 2.583 | <0.001 |
| **Body mass index (per 1 kg/m$^2$)** | 1.000 | 0.965 – 1.035 | 0.989 |
| **Waist hip ratio (per 0.01)** | 1.054 | 1.033 – 1.075 | <0.001 |
| **Pulse pressure (per 1 mmHg)** [‡] | 1.007 | 1.000 – 1.013 | 0.035 |
| **Hypertension** | 1.287 | 0.861 – 1.923 | 0.218 |
| **Diabetes** | 2.459 | 1.867 – 3.238 | <0.001 |
| **Cardiovascular diseases** [§] | 1.315 | 1.005 – 1.720 | 0.046 |
| **Smoking history** | 1.703 | 1.299 – 2.231 | <0.001 |
| **ECW/TBW (per 0.01)** | 1.297 | 1.147 – 1.467 | <0.001 |
| **Laboratory findings** | | | |
| eGFR (per 1 mL•min-1•1.73 m$^{-2}$) | 0.988 | 0.983 – 0.992 | <0.001 |
| Hemoglobin (per 1 g/dL) | 0.879 | 0.820 – 0.942 | <0.001 |
| Total cholesterol (per 1 mg/dL) | 0.991 | 0.987 – 0.995 | <0.001 |
| LDL (per 1 mg/dL) | 0.988 | 0.983 – 0.993 | <0.001 |
| HDL (per 1 mg/dL) | 0.987 | 0.977 – 0.998 | 0.021 |
| Triglyceride (per 1 mg/dL) | 0.999 | 0.997 – 1.001 | 0.411 |
| Albumin (per 1 g/dL) | 0.538 | 0.371 – 0.779 | 0.001 |
| Calcium (per 1 mg/dL) | 1.184 | 0.884 – 1.586 | 0.258 |
| Phosphate (per 1 mg/dL) | 0.923 | 0.722 – 1.181 | 0.524 |
| hs-CRP (per 1 log) [†] | 0.835 | 0.255 – 3.097 | 0.788 |
| uACR (per 1og) [†] | 1.273 | 0.921 – 1.760 | 0.144 |
| **Medications** | | | |
| Antihypertensive drugs [‖] | 1.232 | 0.886 – 1.712 | 0.215 |
| Lipid lowering agents [#] | 1.346 | 1.025 – 1.769 | 0.033 |
| Diuretics | 1.300 | 0.966 – 1.750 | 0.083 |
| Antithrombotic agents [**] | 1.813 | 1.386 – 2.371 | <0.001 |
| Oral calcium | 1.324 | 0.444 – 3.946 | 0.614 |
| Phosphate binders [ʃ] | 4.494 | 1.000 – 20.200 | 0.050 |

[*]A total Agatston coronary artery calcium score ≥ 400 was defined as coronary artery calcification., [†]log transformed, [‡] Mean value of pulse pressure measured by 24-hour ambulatory blood pressure, [§] Cardiovascular diseases included coronary occlusive disease, ischemic heart disease, congestive heart failure, arrhythmia, atherosclerosis, and cerebrovascular disease., [‖]Antihypertensive drugs included angiotensin receptor blockers, angiotensin-converting enzyme inhibitors, calcium channel blocker, β-blocker, and α-blocker., [#] Lipid lowering agents included statin, fibrate, and nicotinic acid., [**] Antithrombotic agents included aspirin, other anti-platelets and anti-coagulants., [ʃ] Phosphate binders included both calcium-based and non-calcium-based phosphate binders.

OR, odds ratio; CI, confidence interval; ECW/TBW, extracellular water to total body water ratio; eGFR, estimated glomerular filtration rate; Hb, hemoglobin; LDL, Low density lipoprotein cholesterol; HDL, high density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; uACR, urine albumin to creatinine ratio

**Table S4. Reclassification improvement for presence of coronary artery calcification[*] by extracellular fluid status.**

| | | Basic clinical model[†] + ECW/TBW | | | Reclassification | |
|---|---|---|---|---|---|---|
| | | <10% | 10 – 20% | ≥20% | Up | Down |
| **Non-CAC (CAC <400, n =1490)** | | | | | | |
| **Basic clinical model[†]** | <10% | 751 | 11 | 3 | | |
| | 10 – 20% | 40 | 373 | 9 | 23 | 64 |
| | ≥20% | 0 | 24 | 279 | | |
| **CAC (CACS ≥400, n =251)** | | | | | | |
| **Basic clinical model[†]** | <10% | 36 | 2 | 0 | | |
| | 10 – 20% | 4 | 63 | 10 | 12 | 6 |
| | ≥20% | 0 | 2 | 134 | | |

[*] A total Agatston coronary artery calcium score ≥ 400 was defined as coronary artery calcification
[†] Adjusted for age, sex, waist to hip ratio, hypertension, diabetes, cardiovascular disease, smoking status, pulse pressure, estimated glomerular filtration rate, hemoglobin, low-density lipoprotein cholesterol, albumin, calcium, phosphate, and use of lipid lowering agents, antithrombotic agents, and phosphate binders

ECW/TBW, extracellular water to total body water ratio; NRI, net reclassification improvement; IDI, integrated discrimination improvement

**Table S5. Unadjusted and adjusted linear regression analyses of extracellular fluid status for the coronary artery calcium scores[*].**

|  | β | 95% CI | *P* |
|---|---|---|---|
| **ECW/TBW (per 0.01 increase)** | 0.074 | 0.052 – 0.095 | <0.001 |
| **Model 1[†]** | 0.053 | 0.032 – 0.073 | <0.001 |
| **Model 2[‡]** | 0.038 | 0.017 – 0.060 | <0.001 |
| **Model 3[§]** | 0.040 | 0.019 – 0.061 | <0.001 |

[*] Log transformed coronary artery calcium scores
[†] Adjusted for age, sex, waist to hip ratio, hypertension, diabetes, cardiovascular disease, smoking status, and pulse pressure
[‡] Adjusted for model 1 + estimated glomerular filtration rate, hemoglobin, low-density lipoprotein cholesterol, albumin, calcium, and phosphate
[§] Adjusted for model 2 + use of lipid lowering agents, antithrombotic agents, and phosphate binders

ECW/TBW, extracellular water to total body water ratio; OR, odds ratio; CI, confidence interval

**Table S6. Association of ECF status for the presence of coronary artery calcification[*] after additional adjustment of NT-proBNP.**

|  | OR | 95% CI | P |
|---|---|---|---|
| **ECW/TBW (per 0.01 increase)** | 1.941 | 1.474 – 2.554 | <0.001 |
| **Model 1[†]** | 1.530 | 1.099 – 2.129 | 0.012 |
| **Model 2[‡]** | 1.645 | 1.113 – 2.432 | 0.013 |
| **Model 3[§]** | 1.690 | 1.139 – 2.507 | 0.009 |

[*] A total Agatston coronary artery calcium score ≥ 400 was defined as coronary artery calcification

[†] Adjusted for age, sex, waist to hip ratio, hypertension, diabetes, cardiovascular disease, smoking status, and pulse pressure

[‡] Adjusted for model 1 + estimated glomerular filtration rate, hemoglobin, low-density lipoprotein cholesterol, albumin, calcium, phosphate, and log transformed NT-proBNP

[§] Adjusted for model 2 + use of lipid lowering agents. antithrombotic agents, and phosphate binders

ECW/TBW, extracellular water to total body water ratio; OR, odds ratio; CI, confidence interval

**Table S7. Subgroup analysis.**

| | Hypertension group (CAC/total N=65/767) | | | DM with albuminuria group (CAC/total N=152/730) | | | CVD group* (CAC/total N=8/95) | | |
|---|---|---|---|---|---|---|---|---|---|
| | **OR** | **95% CI** | **P** | **OR** | **95% CI** | **P** | **OR** | **95% CI** | **P** |
| **ECW/TBW (per 0.01)** | 1.589 | 1.212 – 2.083 | 0.001 | 1.794 | 1.476 – 2.181 | <0.001 | 0.795 | 0.273 – 2.313 | 0.673 |
| **Model 1[†]** | 1.355 | 0.967 – 1.900 | 0.078 | 1.821 | 1.469 – 2.256 | <0.001 | 1.284 | 0.322 – 5.123 | 0.724 |
| **Model 2[‡]** | 1.875 | 1.183 – 2.971 | 0.007 | 1.869 | 1.411 – 2.476 | <0.001 | 2.183 | 0.398 – 11.981 | 0.369 |
| **Model 3[§]** | 2.036 | 1.271 – 3.261 | 0.003 | 1.867 | 1.409 – 2.473 | <0.001 | 2.843 | 0.383 – 21.115 | 0.307 |

[*] CVD group include asymptomatic peripheral vascular disease, atrial fibrillation, and heart failure patients without diabetes.

[†] Adjusted for age, sex, waist to hip ratio, hypertension, diabetes, cardiovascular disease, smoking status, and pulse pressure

[‡] Adjusted for model 1 + hemoglobin, lipid profiles, albumin, and estimated glomerular filtration rate

[§] Adjusted for model 2 + use of lipid lowering agents and antithrombotic agents

DM, diabetes mellitus; CVD, cardiovascular disease; ECW/TBW, extracellular water to total body water ratio; OR, odds ratio; CI, confidence interval

**Table S8. Unadjusted and adjusted odds ratios of extracellular fluid status for the presence of coronary artery calcification[*] stratified by the severity of chronic kidney disease.**

| | CKD stage 12 (n = 145/1206) | | | CKD stage 3-5 (n = 106/535) | | |
|---|---|---|---|---|---|---|
| | OR | 95% CI | P | OR | 95% CI | P |
| **ECW/TBW (per 0.01 increase)** | 1.094 | 1.014 – 1.182 | 0.021 | 1.820 | 1.475 – 2.246 | <0.001 |
| **Model 1[†]** | 1.098 | 1.014 – 1.188 | 0.021 | 1.722 | 1.402 – 2.240 | <0.001 |
| **Model 2[‡]** | 1.109 | 1.021 – 1.205 | 0.014 | 2.166 | 1.580 – 2.970 | <0.001 |
| **Model 3[§]** | 1.113 | 1.024 – 1.209 | 0.011 | 2.238 | 1.627 – 3.078 | <0.001 |

[*] A total Agatston coronary artery calcium score ≥ 400 was defined as coronary artery calcification
[†] Adjusted for age, sex, waist to hip ratio, hypertension, diabetes, cardiovascular disease, smoking status, and pulse pressure
[‡] Adjusted for model 1 + estimated glomerular filtration rate, hemoglobin, low-density lipoprotein cholesterol, albumin, calcium, and phosphate
[§] Adjusted for model 2 + use of lipid lowering agents, antithrombotic agents, and phosphate binders

ECW/TBW, extracellular water to total body water ratio; OR, odds ratio; CI, confidence interval

**Table S9. Association of ECF status for the presence of coronary artery calcification[*] depending on diuretic use.**

| | Diuretics non-user | | | Diuretics user | | |
|---|---|---|---|---|---|---|
| | OR | 95% CI | P | OR | 95% CI | P |
| **ECW/TBW (per 0.01 increase)** | 1.171 | 1.053 – 1.304 | 0.004 | 1.643 | 1.321 – 2.043 | <0.001 |
| **Model 1[†]** | 1.143 | 1.054 – 1.239 | 0.001 | 1.474 | 1.156 – 1.878 | 0.002 |
| **Model 2[‡]** | 1.135 | 1.051 – 1.225 | 0.001 | 2.024 | 1.365 – 3.002 | <0.001 |
| **Model 3[§]** | 1.137 | 1.054 – 1.228 | 0.001 | 2.232 | 1.478 – 3.371 | <0.001 |

[*] A total Agatston coronary artery calcium score ≥ 400 was defined as coronary artery calcification
[†] Adjusted for age, sex, waist to hip ratio, hypertension, diabetes, cardiovascular disease, smoking status, and pulse pressure
[‡] Adjusted for model 1 + estimated glomerular filtration rate, hemoglobin, low-density lipoprotein cholesterol, albumin, calcium, and phosphate
[§] Adjusted for model 2 + use of lipid lowering agents, antithrombotic agents, and phosphate binders

ECW/TBW, extracellular water to total body water ratio; OR, odds ratio; CI, confidence interval